An overview of the GHMonitor, a registry of children treated with Saizen somatropin [recombinant hGH for injection].
Pediatr Endocrinol Rev
; 2 Suppl 3: 324-6, 2005 Feb.
Article
en En
| MEDLINE
| ID: mdl-16456499
ABSTRACT
The GHMonitor, introduced in 1998, monitors demographics and outcomes in children treated with Saizen (somatropin [recombinant hGH for injection]). Follow-up data are available on 697 patients. The proportion of male to female patients receiving growth hormone (GH) treatment was 6733. Severity of the height deficit present at enrollment varied by diagnosis with patients with Turner syndrome being shortest [height standard deviation score (SDS)=-3.7+/-1.7] and those with organic GH deficiency the least severely stunted (height SDS=-1.9+/-1.5). Forty-eight patients (6.9%) discontinued participation in the registry. The most common reason for discontinuing GH was completion of growth; the second was family relocation. There were 53 adverse events reported in 33 patients in 1977 patient-years of followup. Most were self-limited but 13 were serious, and 5 resulted in discontinuation of treatment. Data from The GHMonitor provide a real world glimpse of current North American GH treatment practices.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Sistema de Registros
/
Hormona de Crecimiento Humana
/
Trastornos del Crecimiento
Límite:
Child
/
Humans
Idioma:
En
Revista:
Pediatr Endocrinol Rev
Asunto de la revista:
ENDOCRINOLOGIA
/
PEDIATRIA
Año:
2005
Tipo del documento:
Article
País de afiliación:
Estados Unidos